Halcyon Medical Devices (HLCN) — Senior Notes 5.90%
Executive Summary
Demo purchase of $100M face of Senior Notes 5.90% at 96.5 (cash investment $97.0M): current yield 6.1%, yield to maturity 6.7%. Recommendation: HOLD. Credit score 98/100 (Low risk). Base-case IRR 7.1%, downside 3.8%, severe -3.5%; probability-weighted IRR 4.6% vs a 12% hurdle; weighted P(default) 0%; severe-case valuation recovery 100%. HOLD (do not size yet): Base-case IRR clears hurdle (7.1% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (4.6% vs ≥ 12.0%); Entry yield meets minimum (6.7% vs ≥ 9.0%).
Investment Thesis
Defensive, cash-generative credit with ample asset and enterprise-value coverage. The 2031 notes at a ~4-pt discount offer a mid-single-digit-plus yield with strong downside protection.
The question: Does a 6.7% yield on a rank-3 unsecured claim compensate for 0% probability-weighted default risk and 0% severe-case loss?
Company Overview
Diversified maker of cardiac and orthopedic implants with sticky surgeon relationships. HQ Minneapolis, MN; Healthcare / Medical Devices. FY2025A revenue $1.4B, EBITDA $336M (24.0% margin); total debt $900M, cash $220M. DEMO DATA
Industry / Market
Med-tech demand is non-cyclical and driven by demographics; pricing is set by hospital GPOs, creating modest margin risk but low default risk.
Historical Financial Performance
| $M | FY2022A | FY2023A | FY2024A | FY2025A |
|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.3B | $1.4B |
| % growth | 6.8% | 5.6% | 5.3% | |
| Direct costs / COGS | $407.1M | $428.4M | $445.5M | $476.0M |
| Gross profit (NOI for real estate) | $772.9M | $831.6M | $884.5M | $924.0M |
| % margin | 65.5% | 66.0% | 66.5% | 66.0% |
| Operating expenses (cash, adjusted) | $495.6M | $529.2M | $558.6M | $588.0M |
| EBITDA (company-adjusted basis) | $277.3M | $302.4M | $325.8M | $336.0M |
| % margin | 23.5% | 24.0% | 24.5% | 24.0% |
| D&A | $53.1M | $56.7M | $59.8M | $63.0M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $224.2M | $245.7M | $266.0M | $273.0M |
| Interest expense | $50.2M | $53.2M | $56.1M | $59.1M |
| EBT | $174.0M | $192.5M | $209.9M | $213.9M |
| Taxes | $43.5M | $48.1M | $52.5M | $53.5M |
| Net income (model basis) | $130.5M | $144.4M | $157.4M | $160.4M |
| Capex | $47.2M | $50.4M | $53.2M | $56.0M |
| Working capital & other cash items | $6.7M | $9.6M | $8.4M | $8.4M |
| Free cash flow | $129.6M | $141.1M | $155.6M | $159.0M |
Capital Structure
| Tranche | Rank | Secured | Face value | Rate | Maturity | Mark / price |
|---|---|---|---|---|---|---|
| Revolver | 1 | Yes | $0.0M | S+275bp | 2029-09-30 | — |
| First-Lien Term Loan | 1 | Yes | $400.0M | S+315bp | 2029-09-30 | 99.0 |
| Senior Notes 5.90% | 3 | No | $500.0M | 5.90% | 2031-05-15 | 96.5 |
Total debt $900.0M (2.7x EBITDA); net debt $680.0M; liquidity $470M; loan-to-value through the target tranche 33%.
Credit Analysis
Net leverage 2.0x, EBITDA / interest 5.69x, FCF / debt 17.7%, DSCR 3.6x, liquidity ratio 7.4x. Score components: Leverage 15/15, Coverage 15/15, Liquidity 10/10, Free cash flow 10/10, Maturity risk 10/10, Margin stability 10/10, Revenue stability 8/8, Asset coverage 12/12, Industry risk 8/10. Score change vs FY2024A (same capital structure): 98 → 98 (no material factor change).
Debt Maturity Profile
| Period | Debt due | % of debt | Projected liquidity (Base) | Refinancing requirement |
|---|---|---|---|---|
| FY2029E | $400M | 44% | $1.2B | — |
| 2031 (beyond horizon) | $500M | 56% | $1.1B | — |
| Tranche | Matures | Balance at maturity | Cash on hand | Net lev. (test ≤) | Pro-forma coverage (test ≥) | Refi rate | Interest burden after | Result | Resolution |
|---|---|---|---|---|---|---|---|---|---|
| Revolver | FY2029E | $0.0M | $760M | 0.3x (8.5x) | 7.39x (1.20x) | 7.0% | $0.0M | REFINANCING PASS | Repaid from cash |
| First-Lien Term Loan | FY2029E | $384.0M | $760M | 0.3x (8.5x) | 7.39x (1.20x) | 7.0% | $0.0M | REFINANCING PASS | Repaid from cash |
Base Case
Revenue CAGR 5.0%; FY2030E EBITDA $443M (24.8% margin); trough EBITDA $353M; peak net leverage 1.4x; minimum EBITDA / interest 5.97x; cumulative FCF $1.0B. No payment default modelled. IRR 7.1%, MOIC 1.21x.
Downside Case
Revenue CAGR 0.0%; FY2030E EBITDA $319M (22.8% margin); trough EBITDA $288M; peak net leverage 1.8x; minimum EBITDA / interest 4.51x; cumulative FCF $730M. No payment default modelled. IRR 3.8%, MOIC 1.11x.
Severe Downside
Revenue CAGR -3.8%; FY2030E EBITDA $243M (21.0% margin); trough EBITDA $218M; peak net leverage 2.2x; minimum EBITDA / interest 3.13x; cumulative FCF $518M. No payment default modelled. IRR -3.5%, MOIC 0.90x.
Covenant Analysis
| FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
|---|---|---|---|---|---|
| Current metric | 1.45x | 0.87x | 0.32x | -0.20x | -0.75x |
| Covenant | ≤ 4.50x | ≤ 4.50x | ≤ 4.50x | ≤ 4.50x | ≤ 4.50x |
| Headroom | 3.05x (68%) | 3.63x (81%) | 4.18x (93%) | 4.70x (104%) | 5.25x (117%) |
| Status | PASS | PASS | PASS | PASS | PASS |
| FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
|---|---|---|---|---|---|
| Current metric | 1.77x | 1.39x | 0.89x | 0.40x | -0.16x |
| Covenant | ≤ 4.50x | ≤ 4.50x | ≤ 4.50x | ≤ 4.50x | ≤ 4.50x |
| Headroom | 2.73x (61%) | 3.11x (69%) | 3.61x (80%) | 4.10x (91%) | 4.66x (103%) |
| Status | PASS | PASS | PASS | PASS | PASS |
Recovery Analysis
If the company defaults, recovery value is $2.2B (going concern) in the severe case → 100% recovery (0% LGD) on the target tranche; downside 100%. Recovery value = MAX(going concern $1.7B, liquidation $527M) + cash, less administrative costs; severe case struck at FY2027E.
| Claim (by seniority) | Rank | Claim | Recovery | Recovery % | Loss | Loss % |
|---|---|---|---|---|---|---|
| Recovery value | $2.2B | |||||
| Less: administrative / DIP costs | ($86.9M) | |||||
| First-Lien Term Loan | 1 | $401.9M | $401.9M | 100.0% | $0.0M | 0.0% |
| Senior Notes 5.90% | 3 | $507.4M | $507.4M | 100.0% | $0.0M | 0.0% |
| Total claims | $909.3M | $909.3M | $0.0M | |||
| Equity (residual) | $1.2B | In the money | ||||
Investment Returns
| Base Case | Downside | Severe Downside | |
|---|---|---|---|
| Face value / purchase price / cash investment | $100M / 96.5 / $97.0M UNDERWRITING ASSUMPTION | ||
| Cash interest + exit/recovery proceeds | $17.7M + $100.0M | $17.7M + $90.0M | $17.7M + $70.0M |
| Capital gain / (loss) vs purchase price | $3.5M | ($6.5M) | ($26.5M) |
| MOIC | 1.21x | 1.11x | 0.90x |
| IRR (hurdle 12%) | 7.1% | 3.8% | -3.5% |
Key Risks
- Unsecured, rank 3: $400M of debt ranks ahead.
- Weakest credit-score factor: Industry risk (8.0 of 10 points).
- Reimbursement or tariff pressure
- Product recall / litigation
Key Protections
- Severe-case valuation recovery of 100% covers the 96.5 purchase price (principal protected).
- Coverage of 5.69x EBITDA / interest; EBITDA can fall 82% before coverage reaches 1.0x.
- Moderate leverage: net debt / EBITDA 2.0x.
- Liquidity of $470M (52% of total debt).
- Base-case refinancing tests pass for all 2 maturing tranche(s); 2 are repaid from cash.
Catalysts
- FDA clearance of next-generation implant
- Investment-grade upgrade path
Due Diligence Items
| Item | Status | Priority | Open question |
|---|---|---|---|
| Historical financials tied to filings | In Progress | High | Do model inputs reconcile to audited statements? |
| Quality of earnings / EBITDA add-backs | In Progress | High | How much of adjusted EBITDA is add-backs? |
| Free cash flow conversion | In Progress | High | What is cash conversion after capex and working capital? |
| Competitive position and management | Issue Identified | Medium | Share trend and management track record? |
| Debt documentation review | Not Started | High | Priming / drop-down protections and baskets? |
| Covenant package and definitions | Not Started | High | Covenant EBITDA definition and headroom? |
| Maturity profile and refinancing plan | Not Started | High | Is the refinancing plan credible at current leverage? |
| Industry conditions and pricing | Issue Identified | Medium | Where are we in the industry cycle? |
| Macro and rate sensitivity | Not Started | Low | How does the credit behave at +300 bps? |
Recommendation
HOLD. HOLD (do not size yet): Base-case IRR clears hurdle (7.1% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (4.6% vs ≥ 12.0%); Entry yield meets minimum (6.7% vs ≥ 9.0%).
| Test | Actual | Required | Weight | |
|---|---|---|---|---|
| ✗ | Base-case IRR clears hurdle | 7.1% | ≥ 12.0% | core |
| ✗ | Expected-cash-flow IRR (probability-weighted) clears hurdle | 4.6% | ≥ 12.0% | core |
| ✓ | Downside IRR stays above floor | 3.8% | ≥ 0.0% | core |
| ✓ | Downside recovery meets minimum (valuation waterfall) | 100.0% | ≥ 60.0% | core |
| ✓ | Base-case refinancing succeeds | PASS | PASS | core |
| ✗ | Entry yield meets minimum | 6.7% | ≥ 9.0% | secondary |
| ✓ | Net leverage within maximum | 2.0x | ≤ 6.0x | secondary |
| ✓ | Covenant headroom (base case, minimum) | 67.9% | ≥ 15.0% | secondary |
| ✓ | Principal protected in severe case (recovery ≥ price) | 100 vs 96.5 | recovery ≥ price | secondary |
| ✗ | No unresolved high-priority diligence | 6 open | 0 open | secondary |
What would change my mind?
- EBITDA declines more than 82% from FY2025A (coverage < 1.0x) — or more than 55% (first covenant breaks).
- The entry price is above 84.9: the base case no longer earns the 12% hurdle (assumed price 96.5).
- Severe-case recovery returns the purchase price only if the distressed valuation multiple is at least 0.0x EBITDA (the severe case assumes 8.0x); the question is how much cushion we want.
- Collateral / enterprise value falls more than 65% from the base-case valuation: the tranche starts to take losses.
- Market access weakens: base-case pro-forma coverage at refinancing is 7.39x vs the 1.20x test, at an assumed 7.0% refinancing rate — a higher spread or lower EBITDA flips the test.
Sources (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
Generated entirely from the structured model (inputs → analysis → memo): every figure reconciles to the Excel workbook (see Settings → Reconciliation). Hypothetical terms are underwriting assumptions. Not investment advice.